ABSI - NASDAQ
Absci Corporation
$5.94
-6.5%Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
At a Glance
Live SnapshotAbsci Corporation Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Absci Corporation Balance Sheet
ABSI • NASDAQ
| Absci Corporation Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
20M | 41.2M | 72.4M | 60M | 252.6M | 69.9M | 13.1M | |
124.3M | 71.2M | 25.3M | 104.5M | 0.0 | 0.0 | 0.0 | |
144.3M | 112.4M | 97.7M | 164.4M | 252.6M | 69.9M | 13.1M | |
0.0 | 0.0 | 2.2M | 1.6M | 1.4M | 1.6M | 222K | |
0.0 | 0.0 | 2.2M | 0.0 | 0.0 | 1.6M | 0.0 | |
0.0 | 0.0 | 0.0 | 1.6M | 1.4M | 0.0 | 222K | |
0.0 | 0.0 | 0.0 | 15M | 10.5M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 5.9M | 8.6M | 1.8M | 339K | |
5.3M | 21.4M | 20.7M | 0.0 | 0.0 | 0.0 | 0.0 | |
149.6M | 133.8M | 120.6M | 186.9M | 273.1M | 73.2M | 13.6M | |
NON-CURRENT ASSETS | |||||||
23.8M | 33.1M | 45.8M | 58M | 58.7M | 13.4M | 5M | |
0.0 | 0.0 | 0.0 | 21.3M | 21.3M | 0.0 | 0.0 | |
41.5M | 44.9M | 48.3M | 51.6M | 55M | 0.0 | 283K | |
41.5M | 44.9M | 48.3M | 73M | 76.3M | 0.0 | 283K | |
0.0 | 0.0 | 0.0 | 1.9M | 16.8M | 0.0 | 790K | |
0.0 | 0.0 | 0.0 | 17.7M | -16.8M | 0.0 | -790K | |
1.4M | 1.8M | 2.6M | -16.4M | 18.1M | 2M | 531K | |
66.7M | 79.8M | 96.7M | 134.1M | 153.1M | 15.3M | 5.8M | |
216.3M | 213.6M | 217.3M | 321M | 426.2M | 88.6M | 19.5M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
2.8M | 3.5M | 1.5M | 2.4M | 8.4M | 2.1M | 268K | |
2.8M | 3.5M | 1.5M | 2.4M | 8.4M | 2.1M | 268K | |
16.6M | 6.8M | 6.6M | 20.5M | 17.4M | 1.6M | 532K | |
873K | 2.7M | 3.3M | 2.9M | 2.4M | 1.5M | 1.2M | |
1.8M | 1.7M | 2.3M | 4M | 4.3M | 2.2M | 686K | |
739K | 1.1M | 3.2M | 445K | 1.4M | 0.0 | 780K | |
0.0 | 12.8M | 12.8M | 0.0 | 0.0 | 2.6M | 0.0 | |
22.8M | 28.7M | 29.6M | 30.3M | 33.9M | 10.1M | 3.5M | |
NON-CURRENT LIABILITIES | |||||||
3.5M | 1.3M | 4.7M | 8M | 1.1M | 4.1M | 1.7M | |
436K | 0.0 | 966K | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 186K | 238K | 743K | 0.0 | 0.0 | |
1M | 133K | 109K | 35K | 12.2M | 749K | 53M | |
4.1M | 5.8M | 11.6M | 16.3M | 26.2M | 11.5M | 57.2M | |
4.4M | 6.1M | 8M | 12.1M | 16.5M | 8.8M | 3.1M | |
26.8M | 34.5M | 41.1M | 46.6M | 60.1M | 21.6M | 60.6M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 156.4M | 52.8M | |
15K | 12K | 9K | 9K | 9K | 2K | 2K | |
813.6M | 688.7M | 582.7M | 570.5M | 557.1M | 635K | 215K | |
-624.8M | -509.6M | -406.5M | -295.9M | -191M | -90.1M | -41.4M | |
591K | -4K | -37K | -120K | -13K | 0.0 | -52.8M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.0 | 0.0 | |
189.4M | 179.1M | 176.2M | 274.4M | 366.1M | 67M | -41.2M | |
189.4M | 179.1M | 176.2M | 274.4M | 366.1M | 67M | -41.2M | |
SUMMARY | |||||||
216.3M | 213.6M | 217.3M | 321M | 426.2M | 88.6M | 19.5M | |
124.3M | 71.2M | 25.3M | 106.3M | 16.8M | 0.0 | 790K | |
5.3M | 10.1M | 15.9M | 23M | 20M | 14.5M | 6M | |
-14.7M | -31.1M | -56.5M | -37M | -232.6M | -55.4M | -7.1M | |
149,522,647 | 149,522,647 | 149,522,647 | 149,522,647 | 149,522,647 | 149,522,647 | 149,522,647 |
SEC Filings
ABSI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 14, 2026 | January 14, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | October 31, 2025 | 2025 |
Related Guides
Continue your ABSI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.